BigBear.ai heads into its August 4 earnings report with nearly a third of its float sold short, borrow availability at zero, and the stock down 23% over the past month — a setup where the lending market alone tells most of the story.
The borrow picture is about as tight as it gets. Availability has been at or near zero for almost the entire past six weeks, meaning every share in the lending pool is already committed to an existing short. That's the most extreme reading of the past year — the 52-week minimum availability is zero, and that floor has been hit repeatedly since early June. Despite that, cost to borrow has actually eased, dropping 28% on the week to roughly 2.2% annualised. The combination — near-zero availability alongside a falling borrow rate — suggests shorts already have their positions locked in and aren't scrambling to add. Short interest itself has edged down about 2% on the week to 31.9% of the free float, though it's still up 11% over the past month. The ORTEX short score sits at 72, ranking BBAI in the 4th percentile for short score and the 2nd percentile for borrow availability across the universe — both extremes. Options traders are conspicuously calm by contrast: the put/call ratio of 0.32 is almost exactly in line with its 20-day average, z-score barely negative, nowhere near the 52-week defensive extreme of 0.44. Shorts are pressing hard; options buyers are not hedging any harder than usual.
The Street view on BBAI is thin and directionally mixed. Only two firms cover the name with meaningful recent activity — HC Wainwright maintains a Buy with a $6 target, while Cantor Fitzgerald sits at Neutral with a $5 target, both set back in March after a round of target cuts. At $3.10, both targets imply meaningful upside on paper, but the bear case is hard to dismiss. Revenue fell to $33.1 million in Q3 2025 from $41.5 million a year prior, full-year guidance was slashed from $160–$180 million to $125–$140 million, and gross margin has compressed to 22.4%. The bull case rests on the Ask Sage ARR ramp — the company expects roughly $25 million in recurring revenue this year from that product, a claimed six-fold increase year-on-year — and on defence-adjacent policy tailwinds. The EV/EBITDA multiple of –55x and a price-to-book near 27x are artefacts of deeply negative earnings, not useful valuation anchors in the traditional sense.
Institutional ownership adds a layer of nuance. BlackRock added nearly 2 million shares in the quarter ended June 30, bringing its stake to 7.5% of shares outstanding. Mirae Asset added close to 1.9 million shares over the same period. Goldman Sachs, by contrast, trimmed by 1.4 million shares. The pattern — index managers adding passively, an active name cutting — is consistent with flows driven by index mechanics rather than fundamental conviction.
Insider activity is worth noting, though not alarming in isolation. The CEO, CFO, and General Counsel all sold small tranches on June 30 at $3.60, following similar small sells in April and May. The 90-day net across all insiders is a modest 141,000 shares sold, worth roughly $524,000 — not a scale that signals urgency, but the direction is uniformly one way.
Post-earnings reactions at BBAI have been inconsistent. The June 9 print produced a 6.7% one-day drop and an 8.1% five-day slide. The May 5 print did the opposite, adding 4.8% on the day. With the next event on August 4, the setup is less about which direction the stock moves and more about whether the revenue trajectory shows any inflection — or whether the guidance cut from late 2025 proves to have been too optimistic in its own right.
See the live data behind this article on ORTEX.
Open BBAI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
